Merakris Therapeutics Selected as Finalist for 2025 Advanced Would Care Summit Innovation Showcase
MTX-001, an investigational new drug, aims to become the first subcutaneous biologic drug therapy for chronic non-healing venous leg ulcers
RESEARCH TRIANGLE PARK, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces its amniotic fluid-derived regenerative biologic, MTX-001, an investigational new drug, is a finalist for the Innovation Showcase: Early-Stage Disruptors in Wound Care at the 2025 Advanced Wound Care (AWC) Summit in Boston. Only six companies were chosen by the AWC selection committee to present at the event on July 17, 2025 at 8:30am ET.
At the Innovation Showcase, Chris Broderick, Merakris Therapeutics CEO, will present an overview of MTX-001, including promising key findings from the ongoing Phase 2 clinical trial evaluating the therapy in patients with non-healing venous leg ulcers (VLUs) also referred to as venous stasis ulcers (VSUs).
“Non-healing VLUs affect millions of people and a substantial number of patients fail to heal with today’s standard therapies,” said Broderick. “MTX-001 represents a new class of regenerative biologics delivered via subcutaneous injection. This innovation is proving to promote healing in chronic venous wounds and improve patient outcomes.”
Also at the 2025 Advanced Wound Care Summit, Sean O'Connell, PhD, Head of Medical Affairs at Merakris Therapeutics, will present “Injectable Drugs as the Next Big Step for Advanced Wound Care” on July 16th at 3:15pm. His talk will review the MTX-001 clinical program, interim Phase 2 results, and outline upcoming plans for a Phase 3 clinical trial. He will also highlight the unmet needs in the chronic wound market and the emerging role of injectable biologics in outpatient care.
For strategic partnership and collaboration opportunities, please visit https://merakris.com/partnerships.
For more information about the MTX-001 clinical trial or Merakris’ Expanded Access Program, please contact medaffairs@merakris.com.
About Merakris Therapeutics
Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies.
Merakris Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris’ products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Merakris’ management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA.
PR Contact: Garth Miller Nova Marketing Solutions garth.miller@novamktsolutions.com 919-923-3505
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
